Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
Effects of AT1 receptor antagonist telmisartan on the primary endpoint inflammatory
parameters in patients with coronary artery disease (CAD). Secondary endpoints are
alterations in clinical course and blood pressure